These engineered T cells exhibited dual-antigen recognition of tumor cells: in the presence of Her2 alone, T cells exerted cytotoxic effects, whereas co-expression of Her2 and CD19 abrogated killing in favor of local immunomodulation. Here, ERBB2 is linked to neoplasm.